Long-term effects of fenofibrate on serum lipids and on lipoprotein cholesterol in type II hyperlipoproteinemic patients
- 1 August 1984
- journal article
- research article
- Published by Elsevier BV in Pharmacological Research Communications
- Vol. 16 (8), 809-820
- https://doi.org/10.1016/s0031-6989(84)80057-0
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- The LDL Receptor Defect in Familial Hypercholesterolemia: Implications for Pathogenesis and TherapyMedical Clinics of North America, 1982
- Inactivation of 3-hydroxy-3-methylglutaryl coenzyme a reductase in cultured human blood mononuclear cells by procetofenic acidPharmacological Research Communications, 1982
- Lowering Plasma Cholesterol by Raising LDL ReceptorsNew England Journal of Medicine, 1981
- Regulation of Plasma Cholesterol by Lipoprotein ReceptorsScience, 1981
- Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.Proceedings of the National Academy of Sciences, 1980
- Mode of action of the lipid-lowering agents, clofibrate and BM 15075, on cholesterol biosynthesis in rat liverAtherosclerosis, 1978
- Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductaseJournal of Biological Chemistry, 1978
- New micromethod for measuring cholesterol in plasma lipoprotein fractions.Clinical Chemistry, 1977